| Autor: |
Suah JL; COVID-19 Immunisation Task Force, Government of Malaysia, Putrajaya 62000, Malaysia., Tok PSK; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, Malaysia., Ong SM; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, Malaysia., Husin M; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, Malaysia., Tng BH; COVID-19 Immunisation Task Force, Government of Malaysia, Putrajaya 62000, Malaysia., Sivasampu S; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, Malaysia., Thevananthan T; COVID-19 Immunisation Task Force, Government of Malaysia, Putrajaya 62000, Malaysia., Appannan MR; Disease Control Division, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Muhamad Zin F; Medical Development Division, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Mohd Zin S; Medical Development Division, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Yahaya H; Disease Control Division, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Rusli N; Disease Control Division, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Ujang MF; Medical Development Division, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Mohd Ibrahim H; Office of Director-General, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Abdullah NH; Office of Director-General, Ministry of Health Malaysia, Putrajaya 62590, Malaysia., Peariasamy KM; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam 40170, Malaysia. |
| Abstrakt: |
Malaysia rolled out a diverse portfolio of predominantly three COVID-19 vaccines (AZD1222, BNT162b2, and CoronaVac) beginning 24 February 2021. We evaluated vaccine effectiveness with two methods, covering 1 April to 15 September 2021: (1) the screening method for COVID-19 (SARS-CoV-2) infection and symptomatic COVID-19; and (2) a retrospective cohort of confirmed COVID-19 cases for COVID-19 related ICU admission and death using logistic regression. The screening method estimated partial vaccination to be 48.8% effective (95% CI: 46.8, 50.7) against COVID-19 infection and 33.5% effective (95% CI: 31.6, 35.5) against symptomatic COVID-19. Full vaccination is estimated at 87.8% effective (95% CI: 85.8, 89.7) against COVID-19 infection and 85.4% effective (95% CI: 83.4, 87.3) against symptomatic COVID-19. Among the cohort of confirmed COVID-19 cases, partial vaccination with any of the three vaccines is estimated at 31.3% effective (95% CI: 28.5, 34.1) in preventing ICU admission, and 45.1% effective (95% CI: 42.6, 47.5) in preventing death. Full vaccination with any of the three vaccines is estimated at 79.1% effective (95% CI: 77.7, 80.4) in preventing ICU admission and 86.7% effective (95% CI: 85.7, 87.6) in preventing deaths. Our findings suggest that full vaccination with any of the three predominant vaccines (AZD1222, BNT162b2, and CoronaVac) in Malaysia has been highly effective in preventing COVID-19 infection, symptomatic COVID-19, COVID-19-related ICU admission, and death. |
